ADC Therapeutics (NYSE:ADCT – Get Rating) released its earnings results on Monday. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.54, MarketWatch Earnings reports. During the same period in the previous year, the company earned ($0.67) EPS.
Shares of NYSE:ADCT opened at $7.81 on Tuesday. The company has a market cap of $538.05 million, a P/E ratio of -2.60 and a beta of 1.85. The company has a debt-to-equity ratio of 0.75, a quick ratio of 6.95 and a current ratio of 7.10. ADC Therapeutics has a one year low of $7.41 and a one year high of $32.00. The business’s 50-day simple moving average is $13.48 and its 200 day simple moving average is $18.06.
Several equities analysts recently weighed in on the company. Morgan Stanley increased their target price on ADC Therapeutics from $29.00 to $30.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 12th. HC Wainwright cut their price objective on ADC Therapeutics from $55.00 to $54.00 and set a “buy” rating on the stock in a report on Friday, March 4th. Finally, Zacks Investment Research upgraded ADC Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, January 21st. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, ADC Therapeutics has an average rating of “Buy” and an average target price of $39.17.
About ADC Therapeutics (Get Rating)
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL).
- Get a free copy of the StockNews.com research report on ADC Therapeutics (ADCT)
- Intuitive Surgical is an Intuitive Buy
- Follow The Money To Cigna
- The Low In Lordstown Motors May Not Be The Last
- MarketBeat Podcast: Barbell Strategy To Strengthen Your Portfolio
- Time to Buy These 3 Oversold Mid-Caps
Receive News & Ratings for ADC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.